Business
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events: TD Cowen 46th Annual Health Care Con
About this update from Sionna Therapeutics, Inc.
[{"type":"image","alt":"Sionna Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Sionna Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/9f8d8c0e203777999006c0b8c8d0c418"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tV.lxsbkEH4l9r3Dfcm34Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9f8d8c0e203777999006c0b8c8d0c418","width":300,"height":300}},"lazy":false},{"type":"text","content":"WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events:","length":463,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"TD Cowen 46th Annual Health Care Conference on Monday, March 2nd, 2026, at 2:30 p.m. ET; and","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"Leerink Partners Global Healthcare Conference 2026 on Tuesday, March 10th, 2026, at 1:40 p.m. ET","length":96,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":188,"olType":false},{"type":"text","content":"Live webcasts of the presentations can be accessed in the ‘Investors’ section of Sionna’s website at https://investors.sionnatx.com/. Replays will also be available following the events.","length":191,"tagName":"p"},{"type":"text","content":"About Sionna Therapeutics Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of l...